Mr. Jonathan Robinson reports

VENTRIPOINT DIAGNOSTICS ANNOUNCES SHAREHOLDER UPDATE AND TELECONFERENCE

Ventripoint Diagnostics Ltd. will hold a teleconference on June 14 at which an update to shareholders will be provided.

"During the first quarter we focused on effecting leadership change in the company and assessing the status of the technology, user base, operations and commercialisation. The Ventripoint team worked closely with our EU and UK distributors to improve sales and customer support processes and decided against renewing agreements with non-performing US distributors. We effectively controlled our operating expenses and updated internal plans and forecasts to identify capital requirements for 2024. The Company is now in the process of implementing CRM and new project management software and is adopting a product management discipline. These changes are positioning Ventripoint to become better aligned with patient and clinician needs and to support revenue generation and growth" said Hugh MacNaught, Ventripoint President & CEO.

"We remain committed to enhancing the level of care provided to the 13 million worldwide sufferers of congenital heart defects with affordable, accurate and reliable measurements of heart structure and function and intend to establish market leadership by 2025. Concurrently the Company is actively identifying additional clinical indications and market segments in which VMS+ offers a clear value proposition."

Highlights include:

Sale of a second unit to Duke University Hospital

Migration of the corporate website to a new platform

Sponsorship of the AEPC conference in Porto, Portugal and delivery of two hands-on workshops with VMS+

Submission of VMS+ V4.0 to FDA for 510(k) clearance

Recruitment of two members to the marketing team

Annual MDSAP audit

Regulatory approval of VMS+ in New Zealand

Selection of a regulatory consultant for Brazil

Initiation of financing of up to $3M CAD through convertible debentures

In other news, the Company's financial results for the first quarter ended March 31, 2024, and the related MD&A, have been filed and are available on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca.

The Company wishes to invite its shareholders to a teleconference to be held on Friday, June 14, 2024, at 11:00 am EST.

*bullet* Participants can access the call by dialing 1-844-763-8274 or +1-647-484-8814. It is recommended that you call 10 minutes before the scheduled start time to avoid the queue.

*bullet* After the call, an audio recording will be made available via telephone for one month, until end of day July 14th. The recording can be accessed by dialing 1-855-669-9658 or +1-604-674-8052 and using the access code 0828#.

*bullet* A written transcript of the call will be available on Ventripoint's website shortly after its conclusion.

For further information, please contact:

Jonathan Robinson JRobinson@oakhillfinancial.ca 416-669-1001 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

We seek Safe Harbor.